Molnupiravir is currently being developed by Merck & Co. Inc. in collaboration with Ridgeback Biotherapeutics, which licensed the drug from DRIVE (founded by Emory chemist Dennis Liotta) in 2020. It could be the first oral antiviral medicine to treat COVID-19. Continue readingMolnupiravir and Drug Development at Emory
DRIVE seeks disease-fighting solutions via a different paradigm than big pharmaceutical industry. The New York Times features an opinion piece titled “In the Race for a Covid-19 Pill, a Little Lab Plays a Big Role.”Continue readingLiotta Group and DRIVE featured in New York Times
Graduate alum Kimberlynn Davis (Liotta Group) shares her career journey in biopharma complete with the twists and surprises on the road to achieve her goals, imperfectly.Continue readingGraduate alum Kimberlynn Davis co-founder of Sidebars podcast
Faculty 411 is a series of articles intended to help demystify the process of applying to faculty jobs. As our department seeks to recruit new faculty colleagues, we want every person to have the information they need to assemble an application that best shows their potential to be successful in a job – at Emory or anywhere!Continue readingWhat is a research statement?
“International work is part of the fabric of Emory University. Our world-class faculty, internationally engaged staff and community of highly talented international students, scholars and alumni develop initiatives and collaborations that have global scope, and the International Awards were established to celebrate these exemplary people as they further Emory’s impact around the world.” Read the…Continue readingDennis Liotta among Emory researchers recognized for global impact
“Achieving efficient delivery of a neuroprotectant into the brain is crucial for acute intervention in neural injury,” said Dennis Liotta, Director, Emory Institute for Drug Development and Samuel Candler Dobbs Professor, Department of Chemistry. “These novel compounds may penetrate the blood brain barrier and, with further testing, could become attractive candidates used to treat stroke and TBI patients.” Read…Continue readingNeuroTrauma Sciences Enters Into Worldwide License Agreement with Emory University for Molecules to Treat Stroke and Traumatic Brain Injury
“This contract underscores our abilities to discover and develop drugs for urgent public health needs. Our goal is to help make the world healthier and less dangerous,” says Dennis Liotta, PhD, executive director of EIDD. Read the full article in the Emory News CenterContinue readingEmory researchers to use $15 million NIAID contract to fight influenza
When reflecting back on his graduate work with the Emory University Department of Chemistry, Kornelius Bankston remembers his scientific endeavors with the Lynn Group to be ambitious. “I had this grandiose idea to develop a therapeutic using amyloid fiber sequences that self-assemble into tubes,” says Kornelius. “That was my big vision statement.” This “think big”…Continue readingKornelius Bankston from bench to business
